SCHEMBL1961585

SCHEMBL1961585

COc1cc(CN(C)C)ccc1N

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.67
HTR7 P34969 4/20 0.54
CYP3A4 P08684 3/20 0.52
TSHR P16473 1/20 0.52
HSD17B10 Q99714 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
HTR1A P08908 1/20 0.49
HTR1D P28221 1/20 0.49
HTR1B P28222 1/20 0.49
HTR2A P28223 1/20 0.49
HTR2C P28335 1/20 0.49
HTR1E P28566 1/20 0.49
HTR2B P41595 1/20 0.49
HTR3A P46098 1/20 0.49
HTR5A P47898 1/20 0.49
HTR6 P50406 1/20 0.49
GAA P10253 1/20 0.47
AOC3 Q16853 1/20 0.45
LMNA P02545 1/20 0.44
MAPT P10636 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30833064 1.00 ALDH1A1 (0.67) ALDH1A1HTR7CYP3A4TSHRHSD17B10
Hydrochloric Acid SCHEMBL27621161 0.98 ALDH1A1 (0.65) ALDH1A1HTR7CYP3A4TSHRHSD17B10
SCHEMBL4528153 0.85 GAA (0.67) ALDH1A1HTR7CYP3A4HTR1AHTR1D
Hydrochloric Acid SCHEMBL5913154 0.84 GAA (0.65) ALDH1A1HTR7CYP3A4HTR1AHTR1D
SCHEMBL5675706 0.82 HTR7 (0.64) ALDH1A1HTR7CYP3A4HTR1AHTR1D
SCHEMBL27868468 0.82 ALDH1A1 (0.62) ALDH1A1HTR7CYP3A4TSHRHSD17B10
SCHEMBL17450407 0.82 ALDH1A1 (0.62) ALDH1A1HTR7CYP3A4TSHRHSD17B10
SCHEMBL2030624 0.82 KDM4E (0.63) ALDH1A1CYP3A4GAAMAPTCYP1A2
SCHEMBL12492648 0.80 ALDH1A1 (0.56) ALDH1A1CYP3A4TSHRHSD17B10TDP1
SCHEMBL273470 0.80 ALDH1A1 (1.00) ALDH1A1CYP3A4TSHRHSD17B10TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240092763-A1 ISOINDOLINONE AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF SINAI HEALTH SYSTEM (CA) 2024-03-21 US disclosed
WO-2022147622-A1 ISOINDOLINONE AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) 2022-07-14 WO disclosed
US-11254696-B2 Dianilinopyrimidine compound for inhibiting kinase activity SHENZHEN TARGETRX, INC. (CN) 2022-02-22 US disclosed
US-20210087213-A1 DIANILINOPYRIMIDINE COMPOUND FOR INHIBITING KINASE ACTIVITY SHENZHEN TARGETRX, INC. (CN) 2021-03-25 US disclosed
EP-3715343-A1 DIPHENYLAMINOPYRIMIDINE COMPOUND FOR INHIBITING KINASE ACTIVITY Shenzhen TargetRx, Inc. (CN) 2020-09-30 EP disclosed
US-9371319-B2 Pyrrolopyridineamino derivatives as MPS1 inhibitors CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2016-06-21 US disclosed
EP-2686318-B1 PYRROLOPYRIDINEAMINO DERIVATIVES AS MPS1 INHIBITORS CANCER REC TECH LTD (GB) 2016-03-09 EP disclosed
EP-2686318-A1 PYRROLOPYRIDINEAMINO DERIVATIVES AS MPS1 INHIBITORS Cancer Research Technology Ltd (GB) 2014-01-22 EP disclosed
CN-103517903-A Pyrrolopyridineamino derivatives as MPS1 inhibitors CANCER REC TECH LTD 2014-01-15 CN disclosed
US-20130345181-A1 PYRROLOPYRIDINEAMINO DERIVATIVES AS MPS1 INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2013-12-26 US disclosed
WO-2007027527-A2 ISOINDOLE-IMIDE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME CELGENE CORPORATION (US) 2007-03-08 WO disclosed
WO-2007027527-A2 ISOINDOLE-IMIDE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME CELGENE CORPORATION (US) 2007-03-08 WO disclosed
US-20070049618-A1 Isoindole-imide compounds and compositions comprising and methods of using the same CELGENE CORPORATION 2007-03-01 US disclosed
US-20070049618-A1 Isoindole-imide compounds and compositions comprising and methods of using the same CELGENE CORPORATION 2007-03-01 US disclosed
US-20070049618-A1 Isoindole-imide compounds and compositions comprising and methods of using the same CELGENE CORPORATION 2007-03-01 US disclosed
US-7067506-B2 Compounds useful for inhibiting Chk1 ICOS CORPORATION (US) 2006-06-27 US disclosed
US-20050245525-A1 Compounds useful for inhibiting CHK1 ICOS CORPORATION (US) 2005-11-03 US disclosed
EP-1379510-A1 ARYL AND HETEROARYL UREA CHK1 INHIBITORS FOR USE AS RADIOSENSITIZERS AND CHAMOSENSITIZERS ICOS CORPORATION (US) 2004-01-14 EP disclosed
US-20030069284-A1 Compounds useful for inhibiting Chk1 ICOS CORPORATION (A WASHINGTON CORPORATION) 2003-04-10 US disclosed
WO-2002070494-A1 ARYL AND HETEROARYL UREA CHK1 INHIBITORS FOR USE AS RADIOSENSITIZERS AND CHAMOSENSITIZERS ICOS CORPORATION (US) 2002-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130345181-A1 PYRROLOPYRIDINEAMINO DERIVATIVES AS MPS1 INHIBITORS BUB1B, BUB1, PPM1D ALDH1A1 2678/4885HTR7 4809/4885CYP3A4 4546/4885
US-20210087213-A1 DIANILINOPYRIMIDINE COMPOUND FOR INHIBITING KINASE ACTIVITY ALK, BRAF, MUSK ALDH1A1 1205/4885HTR7 4095/4885CYP3A4 1557/4885
US-20050245525-A1 Compounds useful for inhibiting CHK1 CHEK1, PCNA, CHEK2 ALDH1A1 3047/4885HTR7 3868/4885CYP3A4 4040/4885
US-20030069284-A1 Compounds useful for inhibiting Chk1 CHEK1, PCNA, CHEK2 ALDH1A1 3047/4885HTR7 3868/4885CYP3A4 4040/4885
US-20070049618-A1 Isoindole-imide compounds and compositions comprising and methods of using the same SI, CYP3A5, CYP2D6 ALDH1A1 1081/4885HTR7 144/4885CYP3A4 16/4885
US-20240092763-A1 ISOINDOLINONE AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF NUAK1, NUAK2, NEK1 ALDH1A1 2148/4885HTR7 4055/4885CYP3A4 3772/4885
US-11254696-B2 Dianilinopyrimidine compound for inhibiting kinase activity ALK, BRAF, MUSK ALDH1A1 1334/4885HTR7 3987/4885CYP3A4 1802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.